Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates
Alireza Shoari1, Mehdi Tahmasebi2, Farnaz Khodabakhsh3
1Biotechnology Research Center, Venom and Biotherapeutics Molecules Laboratory, Pasteur Institute of Iran, Tehran, Iran.
Abstract:
Solid cancers are affiliate on angiogenesis for preservation. The FDA-approved monoclonal antibodies like Bevacizumab are currently being administered effectively as inhibitors of angiogenesis against various types of tumors. Despite the clinical achievements in this regard, monoclonal antibodies suffer from considerable disadvantages, including the potential to develop therapeutic resistance, a high production cost, and the restricted tumor penetration, which consequently limit their therapeutic applications. In the past decades, some significant methods such as miniaturization of the antibodies, containing those inhibiting tumor angiogenesis, have been proposed to enhance cancer therapeutics efficiency. Since their discovery, small single-domain antigen binding antibody fragments, known as nanobodies, have been broadly utilized in the fields of cancer research, diagnosis, and treatment. Due to their desired functional attributes and a unique structure, nanobodies are becoming promising therapeutic and diagnostic biomolecules in oncology field. Moreover, they displayed a substantial translational potential in preclinical and clinical studies. This review was performed with the aim of highlighting the potential of nanobodies in blocking the angiogenic process by targeting of angiogenic biomolecules for cancer therapy and the application of labeled nanobodies in non-invasive in vivo tumor imaging.
Insights
Nanobodies offer a promising alternative to monoclonal antibodies for cancer therapy and imaging. These small antibody fragments overcome limitations like resistance and cost, enhancing treatment and diagnosis for solid tumors.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Solid tumors rely on angiogenesis for growth and survival.
- Current anti-angiogenesis therapies like monoclonal antibodies have limitations including therapeutic resistance, high cost, and poor tumor penetration.
- Nanobodies, small single-domain antibody fragments, have emerged as promising tools in cancer research and treatment.
Purpose of the Study:
- To review the potential of nanobodies in inhibiting tumor angiogenesis for cancer therapy.
- To explore the application of labeled nanobodies for non-invasive in vivo tumor imaging.
Main Methods:
- Review of existing literature on nanobody applications in oncology.
- Analysis of nanobody structure-function relationships relevant to anti-angiogenesis.
- Evaluation of nanobody-based diagnostic and therapeutic strategies.
Main Results:
- Nanobodies demonstrate potential in blocking angiogenic processes by targeting key angiogenic molecules.
- Labeled nanobodies show promise for effective non-invasive in vivo tumor imaging.
- Nanobodies offer advantages over traditional monoclonal antibodies, including better tumor penetration and potentially lower production costs.
Conclusions:
- Nanobodies represent a significant advancement in cancer therapeutics and diagnostics.
- Their unique properties make them valuable for developing novel anti-angiogenic strategies and imaging agents.
- Further preclinical and clinical studies are warranted to fully realize the translational potential of nanobodies in oncology.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...